Health2Sync, a digital health startup based in Taiwan, and the French multinational pharmaceutical company Sanofi have expanded their collaboration to develop and commercialize a new insulin management solution soon.
WHY IT IS IMPORTANT
The companies noted the “sub-optimal” use of insulin in Taiwan and Asia. One recently A study published in the Journal of Diabetes Investigation said that around half of insulin users in Asia failed to meet their glycemic goal after an insulin intervention, mainly due to poor insulin exposure.
It was found in another real world Survey found that one in seven patients on insulin had stopped taking insulin for about one to two months for a variety of reasons, such as: B. Impact on social life and costs. At the time, it was found that about half of patients who did poorly on insulin treatment had glycated hemoglobin.
According to a press release, Health2Sync will develop an insulin management solution with titration algorithms which, according to the company, will be “the first of its kind in Asia”. It found that “timely” titration warnings are “promising” for effective communication between healthcare providers and patients and helpful for patients who want to reach their desired HbA1c level faster.
Sanofi will initially commercialize this upcoming solution in Taiwan once the appropriate regulatory approvals are received.
Ultimately, the partners aim to “bring about clinical efficacy with real evidence of the networked ecosystem and insulin management solution”.
THE BIGGER TREND
The companies joined for the first time a License agreement last year in September. Since then, Health2Sync’s digital solutions have been rolled out to over 180 clinics and hospitals that have been certified by the Taiwan Diabetes Shared Care Network.
Also in November last year, Health2Sync teamed up with an apartment management company Daikyo Astage aims to provide health management services to residents of the apartments it manages in Japan. The SyncHealth app for the management of chronic illnesses was used, which supports users in self-management of long-term illnesses.
ON THE RECORD
“With this new phase of our partnership with Health2Sync, we are accelerating our quest to support the unmet daily needs of people with diabetes in Taiwan with scalable, data-driven solutions that help caregivers transform the healthcare environment and deliver meaningful clinical and real-world health outcomes,” Kelly Lam, general manager of general medicine for Sanofi Hong Kong and Taiwan.